首页> 外文期刊>The Lancet >Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.
【24h】

Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial.

机译:阿莫地喹,磺胺多辛/乙胺嘧啶和联合疗法在乌干达坎帕拉治疗简单的恶性疟疾:一项随机试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Increasing Plasmodium falciparum resistance to chloroquine in sub-Saharan Africa necessitates use of alternative antimalarial agents. Affordable alternative treatments include sulfadoxine/pyrimethamine and amodiaquine. Combination of antimalarial agents can increase therapeutic efficacy and delay emergence of drug resistance. We compared the efficacy of sulfadoxine/pyrimethamine, amodiaquine, and an amodiaquine/sulfadoxine/pyrimethamine combination for treatment of uncomplicated malaria in a region of high chloroquine resistance. METHODS: Patients with symptoms of uncomplicated falciparum malaria and confirmed disease in Kampala, Uganda, were randomly assigned to receive sulfadoxine/pyrimethamine (25 mg/kg sulfadoxine, and 1.25 mg/kg pyrimethamine) plus placebo; amodiaquine (25 mg/kg) plus placebo; or amodiaquine plus sulfadoxine/pyrimethamine. Patients were followed up for 14 days, and clinical and parasitological outcomes were assessed. FINDINGS: 90% (400/445) of patients enrolled in the study successfully completed 14 days of follow-up. Treatment failure based on clinical criteria occurred in 13 of 131 (10%) patients on sulfadoxine/ pyrimethamine, nine of 131 (7%) on amodiaquine, and four of 138 (3%) on amodiaquine/sulfadoxine/pyrimethamine. Based on parasitological criteria, treatment failed in 26%, 16%, and 10% of these patients, respectively. Amodiaquine/sulfadoxine/pyrimethamine was significantly more effective than sulfadoxine/pyrimethamine alone in children aged younger than 5 years (clinical failure in 3.5% vs 13.9%, respectively, risk difference 10.4% [95% CI, 1.6-19.3] p=0.021; parasitological failure in 12.8% vs 26.4%, risk difference 13.6% [1.2-26.0] p=0.041). INTERPRETATION: Sulfadoxine/pyrimethamine, amodiaquine, and amodiaquine/sulfadoxine/pyrimethamine were all effective for treatment of uncomplicated falciparum malaria in Uganda. The amodiaquine/sulfadoxine/pyrimethamine combination was the most effective, and could be the optimum low-cost alternative to chloroquine in Africa.
机译:背景:在撒哈拉以南非洲,恶性疟原虫对氯喹的耐药性不断提高,因此有必要使用其他抗疟药。负担得起的替代疗法包括磺胺多辛/乙胺嘧啶和氨二喹。抗疟药的组合可以提高治疗效果并延迟耐药性的出现。我们比较了磺胺多辛/乙胺嘧啶,氨苯二胺和氨二喹/磺胺二氧胺/乙胺嘧啶组合在高氯喹抗性区域中治疗非复杂性疟疾的功效。方法:在乌干达坎帕拉,患有单纯性恶性疟疾症状且确诊的患者被随机分配接受磺胺多辛/乙胺嘧啶(25 mg / kg磺胺多辛和1.25 mg / kg乙胺嘧啶)加安慰剂。阿莫地喹(25 mg / kg)加安慰剂;或氨二喹加磺胺多辛/乙胺嘧啶。对患者进行了14天的随访,并评估了临床和寄生虫学结局。结果:90%(400/445)的研究患者成功完成了14天的随访。基于临床标准的治疗失败发生于131 mg(10%)的磺胺多辛/乙胺嘧啶患者,131氨氮喹(131%)的9位患者,氨二喹/磺胺多辛/乙胺嘧啶(138%)的4人(3%)。根据寄生虫学标准,这些患者的治疗失败率分别为26%,16%和10%。在5岁以下的儿童中,阿莫地喹/磺胺多辛/乙胺嘧啶的疗效明显优于磺胺多辛/乙胺嘧啶(临床失败率分别为3.5%和13.9%,风险差异为10.4%[95%CI,1.6-19.3] p = 0.021;寄生虫失败率分别为12.8%和26.4%,风险差异为13.6%[1.2-26.0] p = 0.041)。解释:磺胺多辛/乙胺嘧啶,阿莫地喹和氨二喹/磺胺多辛/乙胺均对乌干达单纯性恶性疟疾有效。氨二喹/磺胺多辛/乙胺嘧啶的组合最有效,并且可能是非洲氯喹的最佳低成本替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号